Symbol="IMAB"
AssetType="Common Stock"
Name="I-Mab"
Description="I-Mab, a clinical-stage biopharmaceutical company, discovers, develops and markets biologics to treat cancer and autoimmune disorders. The company is headquartered in Shanghai, the People's Republic of China."
CIK="1778016"
Exchange="NASDAQ"
Currency="USD"
Country="China"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="SUITE 802, WEST TOWER, OMNLVISION, 88 SHANGKE ROAD, PUDONG DISTRICT, SHANGHAI, CHINA"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="232797000"
EBITDA="-1859417984"
PERatio="None"
PEGRatio="None"
BookValue="36.25"
DividendPerShare="0"
DividendYield="0"
EPS="-4.36"
RevenuePerShareTTM="-2.685"
ProfitMargin="0"
OperatingMarginTTM="8.46"
ReturnOnAssetsTTM="-0.242"
ReturnOnEquityTTM="-0.637"
RevenueTTM="-221563008"
GrossProfitTTM="41594000"
DilutedEPSTTM="-4.36"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="1.917"
AnalystTargetPrice="34.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="2.545"
PriceToBookRatio="0.587"
EVToRevenue="0.439"
EVToEBITDA="0.101"
Beta="0.939"
num_52WeekHigh="10.82"
num_52WeekLow="2.61"
num_50DayMovingAverage="3.066"
num_200DayMovingAverage="3.904"
SharesOutstanding="83099000"
DividendDate="None"
ExDividendDate="None"
symbol="IMAB"
open="2.75"
high="2.84"
low="2.72"
price="2.83"
volume="510448.00"
latest_trading_day="2023-07-17"
previous_close="2.79"
change="0.04"
change_percent="1.4337%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="70"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="30"
Volume_recent_avg="330645"
Change_recent_avg="-0.01"
Delta_recent_avg="0.23"
Variance_recent_avg="0.11"
Change_ratio_recent_avg="-0.46"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="30"
Aroon_momentum_negative="70"
image_negative_thumbnail_id_1="125"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0051.jpeg"
image_negative_thumbnail_id_2="99"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0077.jpeg"
image_neutral_thumbnail_id_1="544"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0055.jpeg"
image_neutral_thumbnail_id_2="524"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0075.jpeg"
image_positive_thumbnail_id_1="697"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0011.jpeg"
image_positive_thumbnail_id_2="637"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0071.jpeg"
image_professor_thumbnail_id_1="1183"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0017.jpeg"
image_professor_thumbnail_id_2="1173"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0007.jpeg"
